<DOC>
	<DOC>NCT00255983</DOC>
	<brief_summary>Identifying the role of antibiotics in the treatment of subjects with a microbiologically documented acute exacerbation of chronic bronchitis (AECB) is the purpose of this clinical trial. The trial has been designed to evaluate the efficacy and safety of faropenem medoxomil versus placebo in the treatment of subjects with microbiologically documented AECB.</brief_summary>
	<brief_title>A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis</brief_title>
	<detailed_description>This is a multi-center, multi-national, prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety/tolerability of faropenem medoxomil versus placebo in the treatment of subjects with a primary diagnosis of AECB. All subjects will have a pre-therapy sputum specimen obtained for culture and susceptibility testing.</detailed_description>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis, Chronic</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<criteria>Male or nonpregnant female outpatients age greater than or equal 35 years with significant COPD (GOLD criteria I, IIA or IIB), chronic cough and sputum production and an acute exacerbation Gold criteria III</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>bronchitis</keyword>
	<keyword>AECB</keyword>
</DOC>